
10/534414



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kouhei TOYOOKA, et al.

Title: ISOINDOLINE DERIVATIVES

Appl. No.: Unassigned

Filing Date: Herewith

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56


Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.



TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

All documents listed on the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding International application. Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and JPO. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Milrael O. Kamski By Rog. No. 32, 404

> Harold C. Wegner Attorney for Applicant Registration No. 25,258

Date May 11, 2005

FOLEY & LARDNER LLP Customer Number: 22428 Telephone: (202) 672-5571

Facsimile: (202) 672-5399

JC14 Rec'd PCT/PTO 11 MAY 2005

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Tradema Lice: U.S. DEPARTMENT OF COMMERCE

Under the P number.	aperwork Reduction Act	of 1998	ersons are	e required to respond to a collection of in	n unless it contains a valid OMB control			
	Substitute for form	1449B	PTO	Complète if Known				
INFORMATION DISCLOSURE				Application Number	Unassigned 10/53441			
	STATEMENT BY	APPLI	CANT	Filing Date	. 250000000			
	Date Submitted: N	fav. 11	2005	First Named Inventor	Kouhei TOYOOKA			
· ·				Group Art Unit	Unassigned: And a			
	(use as many sheets	as ne	cessary)	Examiner Name	Unassigned			
Sheet	1	of	1	Attorney Docket Number	074129-0521			

				U.S. PATENT DOCUMENTS	:	
Examiner Initials*		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear

A1 GB 130720 A2 GB 148399		Rhone-Poulenc S.A. Rhone-Poulenc S.A.	02/14/1973	Corresponds to USP 3847921	
	996	Rhone-Poulenc S.A.	08/24/1977		
AA DOT INO OO				Corresponds to USP 4131674	
A3 PCT WO 98	98/42666 A1	Daewoong Pharm. Co., Ltd.	10/01/1998		
A4 PCT WO 98	98/00121 A1	Eli Lilly & Co.	01/07/1999	Corresponds to USP 6313122	

Examiner Initials*	Cite No.1						
	Α5	Chemical Abstracts, Vol. 106, abs. no. 213692	-				
	Α6	Chemical Abstracts, Vol. 106, abs. no. 49944	Ļ				
	A.7	Holv. Chim. Acta, (1985), 68(7), pgs. 2046-2061.	+				
	V8	Tetrahedron, (2000), 56(27), pgs. 4837-4844					
			1				

Examiner	/Noble Jarrell/	Date Considered	11/19/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique classing designation number. *See attached Kinds of U.S. Patent Documents. *Einter Office that issued the document by the two-letter code (WIPO Standard S1.3). *Get a James patent document, the indication of the year of the relight of the Camperor must precedure the still number a pleant document. *Sind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if Enrish Indicates are "Enrishation is called."

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this flow modulo desent to the Chef Information Officer, U.S. Patent and Tradperiant CPU, 0.8 to x 1450, Alexandria, V.A. 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 22313-1450,